Quick answer: Tirzepatide (our GLP-2TZ) and retatrutide (our GLP-3RT) are two closely related research peptides. The difference comes down to one number. Tirzepatide activates two of the body’s receptors (GIP and GLP-1). Retatrutide activates three (GIP, GLP-1, and glucagon). That one extra receptor is why retatrutide is getting so much attention in metabolic research right now.
If you have spent any time reading about peptides, you have probably seen these two names side by side and wondered what actually separates them. This guide breaks it down in plain English: what each one is, what “dual” and “triple” really mean, and what the published studies have found so far.
First, a 30-Second Crash Course
You only need three terms to follow this whole article:
- Receptor: think of it as a lock on the surface of a cell. When the right key fits into it, the cell gets a signal to do something.
- Agonist: a key that turns the lock ON. A “dual agonist” is one molecule shaped to turn two different locks. A “triple agonist” turns three.
- Incretin: the family of gut-hormone signals (GIP and GLP-1 are the big two) that the body uses to help manage blood sugar and appetite signaling. This is the system both of these peptides were designed to study.
That is it. Everything else is detail.
Tirzepatide vs Retatrutide at a Glance
| Tirzepatide (GLP-2TZ) | Retatrutide (GLP-3RT) | |
|---|---|---|
| How many receptors it activates | 2 (GIP + GLP-1) | 3 (GIP + GLP-1 + glucagon) |
| Nickname in the field | Dual agonist | Triple agonist |
| Size | 39 amino acids | 39 amino acids |
| How far along the human trials are | Phase 3 completed and published | Phase 2 published, phase 3 in progress |
| Weight change reported in trials | About 21% average at 72 weeks (highest dose) | About 24% average at just 48 weeks (highest dose) |
| Research sizes at ARG | 30mg and 60mg | 24mg and 48mg |
One honest caveat about those trial numbers: the tirzepatide figure comes from a huge, completed phase 3 study. The retatrutide figure comes from a smaller, earlier phase 2 study. So they are useful reference points, but it was never a head-to-head race under identical conditions.
What Is Tirzepatide (GLP-2TZ)?
Tirzepatide is the peptide that made “dual agonist” a household term in research circles. It is one molecule built to turn two locks at once: the GIP receptor and the GLP-1 receptor.
Why does that matter? The generation before it, semaglutide, only turned one lock (GLP-1). Tirzepatide let researchers ask a brand-new question: what happens when you switch on both gut-hormone systems at the same time, with a single molecule? The published trial results made it one of the most studied peptides of the decade.
We carry it as GLP-2TZ. Same compound you see in the literature as tirzepatide, and the full deep-dive is here: What Is GLP-2TZ? Dual GIP/GLP-1 Receptor Research Guide.
What Is Retatrutide (GLP-3RT)?
Retatrutide takes the same idea one step further. It keeps the two receptors tirzepatide hits, and adds a third: the glucagon receptor.
Glucagon is the interesting part. While GIP and GLP-1 are mostly about signaling around appetite and blood sugar, glucagon signaling is linked to the body spending energy, particularly in the liver, where it is associated with increased fat burning in preclinical studies. So a triple agonist does not just add one more lock. It adds a fundamentally different kind of signal to the mix, which is exactly why researchers are so interested in it.
We carry it as GLP-3RT, and the standalone guide is here: What Is GLP-3RT? Triple-Receptor Agonist Research Guide.
So What Is the Real Difference?
Picture it like this:
- Semaglutide presses one button (GLP-1).
- Tirzepatide presses two buttons at once (GIP + GLP-1).
- Retatrutide presses those same two buttons, plus a third one (glucagon) that works on the energy-spending side instead of just the intake side.
Because the two peptides are so similar everywhere else (same length, same general design, same long-acting modification), comparing them side by side is almost a perfect controlled experiment. Whatever differences show up can mostly be credited to that third receptor. That is why so many labs study the pair together rather than picking just one.
What the Published Studies Say
Both compounds have serious peer-reviewed science behind them, which is rare in the peptide world and a big part of why they dominate the conversation.
- Tirzepatide: the completed SURMOUNT-1 trial reported an average body-weight reduction of about 20.9% over 72 weeks at the highest dose studied. That was a record when it was published.
- Retatrutide: a 2023 phase 2 trial in the New England Journal of Medicine reported an average reduction of about 24.2% in only 48 weeks at the highest dose studied. That beat every incretin-class result published before it, in two-thirds of the time. The larger phase 3 trials (called TRIUMPH) are running now.
The pattern researchers care about: retatrutide reached a bigger effect faster, which fits the theory that adding the glucagon receptor (the energy-spending signal) stacks on top of what the dual approach already does. Whether phase 3 confirms it is one of the most watched questions in metabolic science.
Handling Notes (the Practical Stuff)
At the bench, the two are treated basically the same way:
- Both arrive as lyophilized powder (freeze-dried) in sealed vials. Store cool, dry, and out of light until reconstituted.
- Both carry the same style of fatty-acid modification that makes them long-acting in published pharmacology work.
- Every ARG batch is HPLC-verified at 99%+ purity.
- Once reconstituted: refrigerate, avoid repeated freeze-thaw cycles, and follow your lab’s standard handling window.
Which One Belongs in Which Project?
| If the research question is about… | Start with |
|---|---|
| How GIP and GLP-1 work together, without other variables | Tirzepatide (GLP-2TZ) |
| What the glucagon receptor adds to the picture | Retatrutide (GLP-3RT) |
| Energy expenditure and liver fat pathways | Retatrutide (GLP-3RT) |
| Comparing against the deepest published evidence base | Tirzepatide (GLP-2TZ) |
| Dual vs triple, head to head | Both, side by side |
Labs building the complete set often add GLP-1SG (semaglutide) 5mg as the single-receptor baseline, which gives you the full one-two-three progression in a single catalog.
Frequently Asked Questions
Are tirzepatide and GLP-2TZ the same thing?
Yes. GLP-2TZ is simply our catalog name for the peptide the scientific literature calls tirzepatide. Same with GLP-3RT and retatrutide.
Is retatrutide stronger than tirzepatide?
“Broader” is the more accurate word. It activates three receptors instead of two. Early trials did report bigger average changes in less time, but those were earlier-stage studies, so the field is waiting on phase 3 before calling it settled.
Are the two peptides similar in structure?
Very. Both are 39-amino-acid peptides built on the same design foundation. Retatrutide’s sequence is tweaked so it can also activate the glucagon receptor, which tirzepatide’s cannot.
Why do researchers study them together?
Because they differ by essentially one thing (the third receptor), running them side by side is the cleanest way to see exactly what that third receptor contributes.
What sizes are available?
GLP-2TZ comes in 30mg and 60mg vials, GLP-3RT in 24mg and 48mg vials. All US-synthesized, lyophilized, and HPLC-verified at 99%+ purity.
Research use only: All compounds discussed in this article are supplied strictly for laboratory research purposes. They are not for human or veterinary use, and nothing in this article is medical advice. References to published clinical trials describe the scientific literature and do not describe or endorse any use of research materials.
